Novo Nordisk reports Q1 EPS down 10% to DKK 2.43 Reports Q1 revenue up 7% in local currencies driven by Levemir and Victoza. Revenue increased by 7% in local currencies and by 2% in Danish kroner to DKK 20.3B. Operating profit increased by 15% in local currencies and by 6% in Danish kroner to DKK 8B.
Novo Nordisk gets FDA approval for diabetes mellitus treatments The U.S. FDA announced that it approved Tresiba and Ryzodeg 70/30 to improve blood sugar control in adults with diabetes mellitus. Tresiba is a long-acting insulin analog indicated to improve glycemic control in adults with type 1 and 2 diabetes mellitus. Ryzodeg 70/30 is a mixture of insulin degludec, a long-acting insulin analog, and insulin aspart, a rapid-acting human insulin analog. It is indicated to improve glycemic control in adults with diabetes mellitus. Tresiba and Ryzodeg are manufactured by Novo Nordisk.